Vitiligo – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed prevalence of vitiligo for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the mature markets and Europe and 10 years for the other countries we cover.
All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology’s vitiligo forecast answers the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of vitiligo?
- In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of vitiligo?
- How will improvements in survival change the number of people living with a diagnosis of vitiligo?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of vitiligo over the forecast period?
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following vitiligo subpopulations:
- Diagnosed prevalent cases by disease subtype.
- Diagnosed prevalent cases by total body surface area.
Note: Coverage may vary by country.
Table of contents
- Vitiligo - Epidemiology - Epidemiology Dashboard
- Introduction
- Vitiligo Epidemiology Dashboard
- Introduction
Utsav Patel, M.P.H., is an associate epidemiologist at Clarivate. His areas of interest are cardiovascular diseases and cancer epidemiology. Previously, he worked as a graduate research assistant at City University of New York, where he conducted multi-omics investigations into cancer study funded by the National Institutes of Health. He obtained his M.P.H. in epidemiology and biostatistics from City University of New York.
Katie Myatt, M.S., Senior Epidemiologist, Epidemiology. Prior to joining Clarivate, Ms. Myatt worked as an epidemiologist for local and state public health departments performing infectious disease surveillance, both endemic and epidemic. Her interests are infectious disease epidemiology and cancer epidemiology. She received both her master’s degree in epidemiology and her bachelor’s degree in biology from the University of Louisville in Kentucky.